Chronic pain associated with advanced cancer is commonly treated with strong opioid analgesics, such as fentanyl. Breakthrough pain episodes are sudden and intense flares of pain that "break through" a long-acting continuous treatment, such as a transdermal patch or a slow release tablet. Breakthrough pain episodes are common in cancer patients, often occurring several times a day.
Conference call information:
Akela will host a conference call at 11:00 am, on Wednesday September 5, 2007. Interested parties may also access the conference call by webcast at http://www.akelapharma.com.
The telephone number to access the conference call is 1-800-731-5319. A replay of the call will be available until Wednesday September 12, 2007. The telephone numbers to access the replay are 416-640-1917 and 1-877-289-8525 with code number 21245927#.
About Akela Pharma Inc.
Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation, pain and CNS markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.
Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 82.3 million shares outstanding.
This news release contains certain forward-looking statements that
reflect the curr
|SOURCE AKELA PHARMA INC.|
Copyright©2007 PR Newswire.
All rights reserved